Nalmefene enhances the remyelinating ability of nalfurafine when administered therapeutically at very low doses during experimental autoimmune encephalomyelitis

Abstract Objectives Multiple sclerosis is an immune‐mediated inflammatory disease of the central nervous system. Recently, kappa opioid receptor (KOR) agonists were found to promote remyelination and recovery in models of demyelination. However, the side effects of many full KOR agonists limit clini...

Descrición completa

Detalles Bibliográficos

Principais autores:	Lisa Denny, Katharina Robichon, Nikki Templeton, Mackenzie Kiernan, Thomas E Prisinzano, Bronwyn M Kivell, Anne Camille La Flamme
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2025-01-01
Series:	Clinical & Translational Immunology
Assuntos:	experimental autoimmune encephalomyelitis kappa opioid receptor agonist mu opioid receptor antagonist nalfurafine nalmefene
Acceso en liña:	https://doi.org/10.1002/cti2.70069
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!